US stock · Healthcare sector · Medical Devices
Company Logo

Abbott Laboratories

ABTNYSE

113.24

USD
+0.80
(+0.71%)
Market Closed
26.29P/E
23Forward P/E
1.01P/E to S&P500
198.276BMarket CAP
1.64%Div Yield
Upcoming Earnings
20 Jul-25 Jul
Shares Short
4/29/22
13.46M
Short % of Float
0.79%
Short % of Shares Outs.
0.77%
% Held by Insiders
0.74%
% Held by Institutions
75.39%
Beta
0.72
PEG Ratio
2.00
52w. high/low
142.60/104.63
Avg. Daily Volume
5.61M
Return %
Stock
S&P 500
1 year
(4.01)
(6.46)
3 years
48.18
36.32
5 years
162.37
63.92
Scale: |
High
Low
28.55
23.39
29.31
21.95
27.54
19.80
27.25
21.39
27.08
21.62
34.77
25.89
38.81
31.64
46.50
35.65
51.74
39.00
45.79
36.00
57.77
38.34
74.92
55.58
89.24
65.50
115.14
61.61
142.60
105.36
139.83
104.63
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
14.69
16.79
19.13
19.89
22.73
24.74
25.29
14.11
13.43
13.86
14.16
15.71
17.42
18.10
19.54
24.32
25.19
Earnings per share
1.12
2.34
3.16
3.72
2.99
3.01
3.78
1.66
1.51
3.00
0.95
0.27
1.35
2.09
2.54
3.99
4.37
FCF per share
2.61
2.29
3.92
4.00
4.99
4.76
4.77
1.41
1.72
1.26
1.41
2.54
2.79
2.55
3.23
4.88
4.89
Dividends per share
1.16
1.27
1.41
1.56
1.73
1.87
2.02
0.57
0.89
0.98
1.04
1.06
1.12
1.29
1.45
1.81
1.81
CAPEX per share
0.87
1.07
0.83
0.70
0.66
0.95
1.14
0.74
0.71
0.75
0.76
0.65
0.79
0.93
1.23
1.06
1.07
Book Value per sh.
9.19
11.52
11.32
14.78
14.47
15.56
16.95
16.26
14.27
14.40
13.94
17.72
17.39
17.64
18.51
20.21
19.46
Comm.Shares outs.
1,530
1,543
1,544
1,546
1,547
1,570
1,577
1,548
1,508
1,473
1,473
1,744
1,756
1,763
1,771
1,771
1,767
Avg. annual P/E ratio
19.2
11.2
8.3
6.2
8.1
8.1
7.9
21.3
27.0
15.3
42.4
177.2
47.6
38.3
37.7
30.5
26.3
P/E to S&P500
1.1
0.6
0.4
0.1
0.4
0.5
0.5
1.3
1.5
0.8
1.9
7.5
1.9
1.6
1.0
1.0
1.0
Avg. annual div. yield
5.4%
4.9%
5.4%
6.7%
7.1%
7.7%
6.7%
1.6%
2.2%
2.1%
2.6%
2.2%
1.8%
1.6%
1.5%
1.5%
1.5%
Revenue (m)
22,476
25,914
29,528
30,765
35,167
38,851
39,874
21,848
20,247
20,405
20,853
27,390
30,578
31,904
34,608
43,075
44,514
Operating margin
9.1%
17.7%
19.3%
20.3%
17.3%
14.8%
20.3%
12.0%
12.8%
14.1%
15.3%
6.3%
11.9%
14.2%
15.5%
19.6%
20.5%
Depreciation (m)
1,559
1,855
1,839
2,090
2,624
3,044
2,783
1,719
1,548
1,472
1,353
3,021
3,278
3,014
3,327
3,538
3,116
Net profit (m)
1,717
3,606
4,881
5,746
4,626
4,728
5,963
2,576
2,284
4,423
1,400
477
2,368
3,687
4,495
7,071
7,725
Income tax rate
24.6%
19.3%
19.2%
20.1%
19.0%
9.0%
4.8%
5.5%
31.7%
18.1%
24.8%
84.2%
18.8%
9.6%
10.0%
13.9%
14.3%
Net profit margin
7.6%
13.9%
16.5%
18.7%
13.2%
12.2%
15.0%
11.8%
11.3%
21.7%
6.7%
1.7%
7.7%
11.6%
13.0%
16.4%
17.2%
Working capital (m)
(669)
4,939
5,451
10,264
5,055
8,289
18,042
9,740
4,729
4,969
20,116
11,235
5,620
4,804
8,534
11,134
11,134
Long-term debt (m)
7,010
9,488
8,713
11,266
12,524
12,040
18,085
3,388
3,408
5,871
20,681
27,210
19,359
16,661
19,429
18,252
18,252
Equity (m)
14,054
17,779
17,480
22,856
22,388
24,440
26,721
25,171
21,526
21,211
20,538
30,897
30,524
31,088
32,784
35,802
35,802
ROIC
7.1%
11.8%
17.1%
15.7%
12.0%
11.7%
12.1%
8.1%
7.2%
13.2%
3.6%
0.8%
5.2%
7.6%
8.2%
12.2%
13.2%
Return on capital
6.3%
11.3%
15.4%
14.7%
10.6%
9.5%
10.2%
6.7%
7.8%
12.6%
4.2%
4.3%
5.6%
7.0%
7.7%
11.7%
12.7%
Return on equity
12.2%
20.3%
27.9%
25.1%
20.7%
19.3%
22.3%
10.2%
10.6%
20.9%
6.8%
1.5%
7.8%
11.9%
13.7%
19.8%
21.6%
Plowback ratio
(3.5)%
45.7%
55.5%
58.0%
42.3%
37.9%
46.6%
65.8%
41.2%
67.4%
(9.9)%
(287.6)%
16.6%
38.4%
43.0%
54.7%
54.7%
Div.&Repurch./FCF
50.8%
50.1%
53.8%
52.4%
45.8%
40.3%
73.8%
114.1%
136.1%
198.3%
99.0%
60.3%
45.1%
66.4%
51.8%
63.6%
63.6%
Capital Structure
18 Feb · 2022 | Q4
All numbers in millions
Total liabilities
$ 39,172
Total assets
$ 75,196
Long-term debt
$ 18,252
Cash and equiv.
$ 9,799
Goodwill
$ 23,231
Retained earnings
$ 31,528
Common stock
1,763
Enterprise Value
$ 206,729
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
4,140
7,148
10,249
Receivables
5,425
6,414
6,487
Inventory
4,316
5,012
5,157
Other
1,786
4,845
8,285
Current assets
15,667
20,441
24,239
Acc. Payable
3,252
3,946
4,408
Debt due
1,478
220
754
Other
6,133
7,741
7,943
Current liabilities
10,863
11,907
13,105
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
24.47%
12.23%
3.41%
Cash flow
51.08%
20.16%
13.94%
Earnings
57.31%
132.84%
46.96%
Dividends
25.08%
14.90%
8.20%
Book value
9.21%
3.83%
4.54%
Insider Trading
Type
Shares
Date
Woodgrift Randel William
Exempt
24,000
05/04/22
Woodgrift Randel William
Sale
24,000
05/04/22
Woodgrift Randel William
Exempt
24,000
05/04/22
Starks Daniel J
Sale
6,123
05/03/22
Starks Daniel J
Sale
27,055
05/03/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
7,726
7,328
8,853
10,701
34,608
2021
10,456
10,223
10,928
11,468
43,075
2022
11,895
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.32
0.30
0.70
1.22
2.54
2021
1.01
0.67
1.19
1.12
3.99
2022
1.39
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2019
0.32
0.32
0.32
0.32
1.29
2020
0.36
0.36
0.36
0.36
1.45
2021
0.45
0.45
0.45
0.45
1.81
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Robert Ford
Full-time employees:
113,000
City:
ABBOTT PARK
Address:
100 Abbott Park Rd
IPO:
Mar 1, 1937
Website:
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Recent News
· 17 May, 2022 · The Wall Street Journal
· 12 May, 2022 · The Wall Street Journal
· 11 May, 2022 · The Wall Street Journal
· 18 Apr, 2022 · The Wall Street Journal
· 1 Mar, 2022 · The Wall Street Journal
· 26 Jan, 2022 · The Wall Street Journal
· 16 Jul, 2020 · The Wall Street Journal